Merus NV
- Country
- 🇳🇱Netherlands
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 229
- Market Cap
- $3.6B
- Website
- http://www.merus.nl
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab Vs Pembrolizumab in First-line Treatment of Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 500
- Registration Number
- NCT06525220
- Locations
- 🇰🇷
Site 45, Seoul, Korea, Republic of
🇺🇸Site 36, La Jolla, California, United States
🇺🇸Site 43, Philadelphia, Pennsylvania, United States
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
- Conditions
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 500
- Registration Number
- NCT06496178
- Locations
- 🇺🇸
Site 40, Baton Rouge, Louisiana, United States
🇦🇷Site 45, Córdoba, Argentina
🇦🇺Site 38, Melbourne, Australia
Study Evaluating Zenocutuzumab in Patients with or Without Molecularly Defined Cancers
- Conditions
- Interventions
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 90
- Registration Number
- NCT05588609
- Locations
- 🇺🇸
The Oncology Institute of Hope & Innovation, Whittier, California, United States
🇺🇸Florida Cancer Specialists, Lake Mary, Florida, United States
🇺🇸The Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 576
- Registration Number
- NCT04868877
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori Regina Elena, Roma, Rome, Italy
🇮🇹Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy
🇺🇸START Mountain Region, West Valley City, Utah, United States
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Merus N.V.
- Registration Number
- NCT04100694
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 72
- Registration Number
- NCT03922204
- Locations
- 🇺🇸
Moores Cancer Centre, La Jolla, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 567
- Registration Number
- NCT03526835
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Oncology Consultants, Houston, Texas, United States
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 105
- Registration Number
- NCT03321981
- Locations
- 🇵🇹
Champalimaud Clinical Centre, Lisbon, Portugal
🇵🇹Hopistal San Antonio, Porto, Portugal
🇪🇸Instituto Valenciano de Oncologia, Valencia, Spain
MCLA-117 in Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 62
- Registration Number
- NCT03038230
- Locations
- 🇮🇹
Fondazione Policlinico Tor Vergata, Rome, Italy
🇫🇷Institut Gustave Roussy, Villejuif Cedex, Ile-de-France, France
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
- Conditions
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Merus N.V.
- Target Recruit Count
- 250
- Registration Number
- NCT02912949
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸The Oncology Institute of Hope and Innovation, Cerritos, California, United States
🇺🇸University of California Irvine, Irvine, California, United States